ES2070125T3 - Factor de crecimiento fibroblastico acido mutante. - Google Patents

Factor de crecimiento fibroblastico acido mutante.

Info

Publication number
ES2070125T3
ES2070125T3 ES88202306T ES88202306T ES2070125T3 ES 2070125 T3 ES2070125 T3 ES 2070125T3 ES 88202306 T ES88202306 T ES 88202306T ES 88202306 T ES88202306 T ES 88202306T ES 2070125 T3 ES2070125 T3 ES 2070125T3
Authority
ES
Spain
Prior art keywords
bovine
human
growth factor
fcfa
code
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88202306T
Other languages
English (en)
Inventor
Jnr Kenneth A Thomas
David L Linemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2070125T3 publication Critical patent/ES2070125T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE CONSTRUYEN NUEVOS GENES QUE CODIFICAN FCFA MUTANTES BOVINO Y HUMANO, Y QUE SE DERIVAN DE GENES QUE CODIFICAN FCFA BOVINO Y HUMANO RECOMBINANTES, POR MUTACIONES EN PUNTOS ESPECIFICOS. CADA BLOQUE ESTRUCTURAL DEL GEN SE INSERTA EN UN SECTOR DE EXPRESION QUE SE EMPLEA PARA TRANSFORMAR UN HUESPED APROPIADO. LAS CELULAS HUESPED TRANSFORMADAS PRODUCEN FCFA RECOMBINANTE MUTANTE UNICO HUMANO O BOVINO, QUE SE PURIFICA Y TIENE ACTIVIDAD BIOLOGICA AUMENTADA O MEJORADA EN AUSENCIA DE HEPARINA, EN COMPARACION CON LAS FORMAS NO MUTANTES.
ES88202306T 1987-10-22 1988-10-14 Factor de crecimiento fibroblastico acido mutante. Expired - Lifetime ES2070125T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11260087A 1987-10-22 1987-10-22
US24443188A 1988-09-16 1988-09-16

Publications (1)

Publication Number Publication Date
ES2070125T3 true ES2070125T3 (es) 1995-06-01

Family

ID=26810140

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88202306T Expired - Lifetime ES2070125T3 (es) 1987-10-22 1988-10-14 Factor de crecimiento fibroblastico acido mutante.

Country Status (13)

Country Link
EP (1) EP0319052B1 (es)
JP (1) JPH082309B2 (es)
KR (1) KR970009340B1 (es)
AT (1) ATE117723T1 (es)
AU (1) AU623351B2 (es)
CA (1) CA1340363C (es)
DE (1) DE3852870T2 (es)
DK (1) DK174961B1 (es)
ES (1) ES2070125T3 (es)
IE (1) IE65360B1 (es)
IL (1) IL88034A (es)
NZ (1) NZ226543A (es)
PT (1) PT88824B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392605A1 (en) * 1989-04-13 1990-10-17 Merck & Co. Inc. Method of enhancing acidic fibroblast growth factor expression
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
CA2020720A1 (en) * 1989-07-13 1991-01-14 Shigeko Yamazaki Method for the purification of therapeutically active recombinant acidic fibroblast growth factor
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
WO1992011360A1 (en) * 1990-12-18 1992-07-09 Amgen Inc. Analogs of acidic fibroblast growth factor having enhanced stability and biological activity
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
JP4088111B2 (ja) * 2002-06-28 2008-05-21 日立電線株式会社 多孔質基板とその製造方法、ＧａＮ系半導体積層基板とその製造方法
JP5401312B2 (ja) * 2007-06-29 2014-01-29 第一三共株式会社 組換えＣ−末端α−アミド化酵素誘導体
PL221356B1 (pl) * 2012-04-21 2016-03-31 Wrocławskie Ct Badań Eit & Spółka Z Ograniczoną Odpowiedzialności Zmodyfikowany genetycznie, rekombinowany czynnik wzrostu fibroblastów (FGF1) skoniugowany z nanocząsteczkami metalu lub tlenku metalu, jego sekwencja DNA i aminokwasowa oraz zastosowanie
CH717226B1 (it) * 2020-07-14 2021-09-30 Contrad Swiss Sa Idrogel per applicazione topica efficace nel limitare la degenerazione di tendini e muscoli.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
EP0248819B2 (en) * 1985-09-12 2000-08-30 Scios Inc. Recombinant fibroblast growth factors
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor

Also Published As

Publication number Publication date
CA1340363C (en) 1999-02-02
DE3852870D1 (de) 1995-03-09
JPH02484A (ja) 1990-01-05
KR970009340B1 (en) 1997-06-10
EP0319052B1 (en) 1995-01-25
DK587488A (da) 1989-06-06
PT88824B (pt) 1993-04-30
EP0319052A3 (en) 1990-04-25
KR890006815A (ko) 1989-06-16
DE3852870T2 (de) 1995-08-17
IL88034A0 (en) 1989-06-30
JPH082309B2 (ja) 1996-01-17
NZ226543A (en) 1992-02-25
AU623351B2 (en) 1992-05-14
EP0319052A2 (en) 1989-06-07
IE65360B1 (en) 1995-10-18
ATE117723T1 (de) 1995-02-15
DK587488D0 (da) 1988-10-21
IE883188L (en) 1989-04-22
IL88034A (en) 1994-06-24
DK174961B1 (da) 2004-03-29
AU2430588A (en) 1989-04-27

Similar Documents

Publication Publication Date Title
Herzel et al. Correlations in DNA sequences: The role of protein coding segments
ES2130120T3 (es) Procedimiento para la preparacion de la adnasa humana.
DE69638314D1 (de) Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie
DK0423980T3 (da) Stamcellefaktor
ATE56471T1 (de) Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
ATE113077T1 (de) Stabile integration von dna in bakterielle genome.
ES2092995T5 (es) Metodo para producir celulas que contienen un adn extraño establemente integrado con un numero alto de copia, las celulas producidas por este metodo y el uso de estas celulas para producir polipeptidos codificados por el adn extraño.
DK0830376T3 (da) Fremgangsmåde til fremstilling af erythropoietin, som er fri for animalske proteiner
ES2147720T3 (es) Factor de celulas madre.
BR9712761A (pt) Método para a produção de 1,3- propanodiol e célula hospedeira transformada
ES529023A0 (es) Produccion de activador de plasminogeno de tejido humano, utilizando vectores que codifican proteina de dihidrofolato- reductasa.
SE9102079L (sv) Renad ciliaer neurotropisk faktor
YU46597B (sh) Postupak za proizvodnju hibridni interferoni humanih leukocita
ES551042A0 (es) Un procedimiento para producir glucagon o fragmentos o derivados del mismo en levadura
ES2062982T3 (es) Clonaje y expresion del factor de crecimiento de fibroblasto acido.
DE3852870D1 (de) Saurer Fibroblast-Wachstumsfaktor-Mutant.
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
ES2059330T3 (es) Un cdna codificador de antigeno carcinoembrionico.
NL960017I2 (nl) Expressie van Factor VIII-activiteit in zoogdiercellen.
FI102191B1 (fi) Menetelmä 3-des-hydroksikystatiini C:n tuottamiseksi ja menetelmässä käytettävä DNA-sekvenssi
DE69328992D1 (de) Mutanten von menschlichem Antithrombin III
ES8707554A1 (es) Procedimiento para preparar interferon-a recombinante
ES8600400A1 (es) Un procedimiento para la produccion de histidina
ATE116366T1 (de) Verfahren zur herstellung eines menschlichen ''neutrophil chemotactic factor''-polypeptids.
ES2056123T3 (es) Clonacion del gen que codifica la enzima isoamilasa y su empleo en la produccion de dicha enzima.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 319052

Country of ref document: ES